Accueil / Communiqués / LEO Science & Tech Hub Adds Vladimir Morozov as Senior Director of Bioinformatics

LEO Science & Tech Hub Adds Vladimir Morozov as Senior Director of Bioinformatics

Wednesday, March 6th 2019 at 12:00pm UTC

Science & Tech Hub
, the Boston-based R&D innovation unit of LEO
, announced today the appointment of Vladimir Morozov, Ph.D.,
as Senior Director of Bioinformatics. In this position, Vladimir will
focus on identifying interesting collaborators for LEO, scope out
research and acceleration activities, run collaborative projects and
guide development towards dermatological use-cases.

Vladimir brings over 25 years of experience in business and academia.
His work has focused heavily on genomic data design and analysis, with
recent emphasis on machine and deep-learning methods.

Prior to joining LEO Science & Tech Hub, Vladimir served as a
Bioinformatics Solution Architect at Shire, where he built
machine-learning methods to optimize antibody activity and worked with
wearable technologies to identify digital biomarkers for patients with
Parkinson’s disease and Chronic fatigue syndrome (CFS). Prior to that,
he served as a Senior Computational Biology Scientist at ALS Therapy
Development Institute where he established Next-Generation Sequencing
(NGS) and predictive models from patient data. He has also held
positions at Dana-Farber Cancer Institute and LION Bioscience, Inc.
Vladimir earned a Ph.D. in Chemical Enzymology from Moscow State

Michael Sierra, Vice President of LEO Science & Tech Hub commented:
“With so much of our current research focused on developing new methods
for biomarker discovery and analysis, Vladimir is truly a natural
addition to our team. We are excited by the continued growth of our
Boston office and will look to Vladimir to help drive the direction of a
number of our early-stage projects.”

Vladimir Morozov, Senior Director of Bioinformatics at LEO Science &
Tech Hub stated: “LEO Pharma continues to serve as a strong example of
how to prioritize innovation in science and technology to improve
patient outcomes. The Science & Tech Hub’s unique model allows our team
to pursue cutting-edge projects with disruptive potential. I look
forward to leveraging my background to have a positive impact on the

About LEO Science & Tech Hub

The LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma
dedicated to identifying, developing, and funding innovative solutions
that improve the lives of people with skin diseases. It was founded in
2016 as a catalyst to transform early-stage innovations into solutions
for improving the lives of people with skin diseases. We collaborate,
explore cutting-edge ideas and make investments. We are an agile group
of scientific experts with an entrepreneurial mindset and a vision of
how to give patients control over disease by predicting, diagnosing, and
monitoring conditions. The LEO Science & Tech Hub is based in Cambridge,
Mass. For more information, please visit,
or connect with us at,
on Twitter @LEOscitech
or LinkedIn

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in
medical dermatology with a robust R&D pipeline, a wide range of
therapies and a pioneering spirit. Founded in 1908 and owned by the LEO
Foundation, LEO Pharma has devoted decades of research and development
to advance the science of dermatology, setting new standards of care for
people with skin conditions. LEO Pharma is headquartered in Denmark with
a global team of 5,700 people, serving 80 million patients in 130
countries. In 2017, the company generated net sales of 1.4 billion euro.


Alex Ignatius Costa
LEO Science & Tech Hub

Anthony Karamourtopoulos
374-8800 ext. 104

Source: LEO Science & Tech Hub

Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study –

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …